Clinical Trials Sponsored by Quidel Corporation

Total 6516 results

Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France
Topcon Corporation

Enrolling by invitation

Screening Protocol

Glaucoma

United States
Yuhan Corporation

Completed

A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

Diabetes Mellitus, Type 2 | Neuropathic Pain

Korea, Republic of
Yuhan Corporation

Completed

Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

Arterial Occlusive Diseases | Intermittent Claudication

Korea, Republic of
Mannkind Corporation

Completed

Afrezza® Dosing Optimization Study (DOS)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Yuhan Corporation

Completed

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Non-small Cell Lung Cancer
Tomey Corporation

Completed

Comparative Study of the TOMEY Specular Microscope EM-4000 and the Konan CellChek XL

Corneal and Endothelial Cell Measurements
Irrimax Corporation

Completed

Retrospective Independent Safety Review of Closed Irrisept Study

Adverse Events

United States
Allievex Corporation

Enrolling by invitation

Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE

MPS III B

United States, Germany, Turkey, United Kingdom, Colombia
Axogen Corporation

Completed

Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE)

Symptomatic Neuroma | Chronic Nerve Pain | Morton's Neuroma

United States
Admetsys Corporation

Active, not recruiting

Insulin Balanced Infusion System

Hyperglycemia | Diabetes

United States
Incyte Corporation

Completed

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Vitiligo

United States, Canada, Poland, Spain, Germany, Bulgaria, France, Netherlands
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Glaukos Corporation

Completed

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease

Dry Eye Disease | Kerato Conjunctivitis Sicca

United States
Seikagaku Corporation

Completed

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.

Dry Eye Syndromes

United States
Genelux Corporation

Temporarily not available

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Advanced Stage Cancer (Solid Tumor Disease for 4 Patients) | Acute Myeloid Leukemia (6 Patients)

United States
Pulmonx Corporation

Completed

Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) (LIBERATE)

Emphysema

United States, Netherlands, United Kingdom, Brazil
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium
Pulmonx Corporation

Active, not recruiting

Zephyr Etude Post-Inscription (French Registry)

Emphysema or COPD

France
Incyte Corporation

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Hemodialysis | Renal Impairment

United States
Seikagaku Corporation

Completed

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

Dry Eye Syndromes

United States
Spectranetics Corporation

Completed

STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR) (ILLUMENATE)

Peripheral Arterial Disease

Belgium, Germany, New Zealand, France, United Kingdom, Australia, Poland, Austria, Italy, Spain
Erchonia Corporation

Withdrawn

Effect of Erchonia Laser on Erectile Dysfunction

Erectile Dysfunction

United States
Seikagaku Corporation

Completed

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Lumbar Disc Disease | Intervertebral Disc Disease

United States
Incyte Corporation

Terminated

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States, Spain, Germany
Erchonia Corporation

Terminated

An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain

Diabetic Peripheral Neuropathy

United States
Candela Corporation

Active, not recruiting

Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™

Wrinkle | Pigmented Lesions

United States
Incyte Corporation

Completed

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Cholangiocarcinoma

United States, France, Italy, United Kingdom, Germany, Taiwan, Spain, Belgium, Israel, Korea, Republic of, Japan, Thailand
Incyte Corporation

Completed

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Unresectable or Metastatic Solid Tumors

United States
Candela Corporation

Active, not recruiting

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro™/GentleMax Pro Plus™

Unwanted Fine Facial Hair

United States
Cordis Corporation

Completed

A Multicenter, Open Label, Prospective, Non-Randomized Study Of INCRAFT™ In Subjects With AAA (INNOVATION) (INNOVATION)

Abdominal Aortic Aneurysms

Germany
Glaukos Corporation

Terminated

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Primary Open-Angle Glaucoma

United States
Topcon Corporation

Completed

Topcon DRI OCT Triton With SS-OCT Angio Software Evaluation Study

Fluorescein Angiography Imaging

United States
Incyte Corporation

Withdrawn

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1)

Hand Eczema

United States, Germany, Spain, Czechia, Canada, Poland
Incyte Corporation

Withdrawn

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (TRuE-CHE2)

Chronic Hand Eczema (CHE)

United States, Canada, Spain, Germany, Czechia, Poland, Bulgaria
Masimo Corporation

Completed

Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00029

Healthy

United States
Neuroelectrics Corporation

Active, not recruiting

Home-based Transcranial Direct Current Stimulation (tDCS) for Major Depressive Disorders (MDD)

Major Depressive Disorder

United States
Incyte Corporation

Completed

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Solid Tumor

United States
Incyte Corporation

Completed

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Non-segmental Vitiligo

United States, Spain, Canada, France, Poland, Bulgaria, Germany, Italy
Glaukos Corporation

Completed

Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra

Glaucoma, Open-Angle

Armenia
Glaukos Corporation

Completed

Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents

Subjects With Primary Open-angle Glaucoma (POAG)

Armenia
Incyte Corporation

Completed

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Advanced Malignancies

United States
Invitae Corporation

Completed

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Prostate Cancer

United States
Incyte Corporation

Approved for marketing

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Graft-versus-host Disease (GVHD)

United States
Erchonia Corporation

Completed

Effect of the Erchonia® EVRL OTC™ for the Relief of Diabetic Peripheral Neuropathy Foot Pain

Neuropathy

United States
Adimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

COVID-19

Taiwan
Amorepacific Corporation

Completed

Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1

Irritable Bowel Syndrome With Diarrhea

Korea, Republic of
Incyte Corporation

Terminated

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Hematologic Malignancies

United States, Spain, France, Italy
Haemonetics Corporation

Completed

Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

Transmission, Blood, Recipient/Donor

United States
Incyte Corporation

Withdrawn

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (CITADEL-310)

Mantle Cell Lymphoma

3

Subscribe